Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
December 3, 2025 Off

Fill Finish Pharmaceutical Contract Manufacturing Market Trends and Global Forecasts Report 2025: Ampoules and Vials Expected to Dominate and Long-Term Growth, With Vials Capturing ~50% Share by 2035 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Fill Finish Pharmaceutical Contract Manufacturing Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Fill…

December 3, 2025 Off

GE HealthCare and Mayo Clinic unveil GEMINI-RT: A bold research collaboration in radiation therapy and advanced cancer care

By BusinessWire

GE HealthCare and Mayo Clinic launch GEMINI-RT, a strategic initiative to personalize radiation therapy by integrating imaging, AI, and patient…

December 3, 2025 Off

Animate Biosciences’ AI-Designed Peptides Switch off Inflammation and Fibrosis Drivers Across Human Skin, Lung, Heart and Liver Cells

By BusinessWire

In vitro studies show reductions in key inflammatory and fibrotic markers and signs of pro-regenerative activity SAN FRANCISCO–(BUSINESS WIRE)–Animate Biosciences…

December 3, 2025 Off

RSNA25: Pediatric Study for Bayer’s Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

By BusinessWire

Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast…

December 3, 2025 Off

Biologics Fill Finish Services Market Trends and Global Forecasts Report 2025: Market Strengthens With 240+ Providers, Vials Lead Adoption, Demand to Exceed 28.5 Million Liters by 2035 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Biologics Fill Finish Services Market Industry Trends and Global Forecasts to 2035, by Type of Primary Packaging Container,…

December 3, 2025 Off

Vycellix Prepares for First-in-Human Study of Novel Allogeneic Cell Therapy Powered by Its Universal Cell Engineering Platform

By BusinessWire

– Single-step CD45-engager technology shows robust immune evasion with functional persistence in pre-clinical models – Phase 1 study to evaluate…

December 3, 2025 Off

Biopharmaceutical CDMO Market Forecast to Reach $56.5 Billion by 2033 – Demand for Biologics and Advanced Therapies Fuels Growth at a 9.55% CAGR – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Biopharmaceutical Contract Development and Manufacturing Organization Market Forecast to 2033” has been added to ResearchAndMarkets.com’s offering. The global…

December 3, 2025 Off

Biologics CDMO Market Trends and Investment Forecast to 2033: Features Analysis of Lonza Group, Catalent Pharma Solutions, Samsung Biologics and Other Key Industry Players – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Biologics Contract Development and Manufacturing Organization Market Forecast to 2033” has been added to ResearchAndMarkets.com’s offering. The global…

December 3, 2025 Off

Vaccine Development Competitive Landscape Report 2025: Rising Partnerships and Collaborations Activity to Foster Progress and Innovation in Expanding their Capabilities – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Vaccine Development Companies Landscape: Competitive Landscape, Recent Expansions, Partnerships and Collaborations, Big Pharma Initiatives and Cost Price Analysis”…

December 3, 2025 Off

Inocras, Samsung Medical Center and Seoul St. Mary’s Hospital Researchers Publish Groundbreaking Study with 1,364 Whole-Genomes of Breast Cancer in Nature

By BusinessWire

Landmark study explores the whole genomes of 1,364 breast cancers, uncovering predictive biomarkers that link genomic signatures to potential treatment…

Posts pagination

Previous 1 … 4 5 6 … 6,180 Next

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

December 5, 2025 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine